HYBRITECH TANDEM PSA TEST APPROVED AS DIAGNOSTIC AID
This article was originally published in The Gray Sheet
HYBRITECH TANDEM PSA TEST APPROVED AS DIAGNOSTIC AID in the detection of prostate cancer. The Tandem-R (immunoradiometric), Tandem-E (immunoenzymetric) and Tandem-ERA (automated enzyme immunoassay) assays for quantitative prostate specific antigen measurement become the first PSA blood tests approved for use in detecting the disease.
You may also be interested in...
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
With finite resources, the UK’s regulatory agency responsible for health care products is rapidly addressing COVID-19 medtech issues. But shifting its focus will cause delays elsewhere.